Cerbios Expands HPAI Manufacturing Capacity

Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).

Cerbios announced the installation of a new production line for high potency...
Cerbios announced the installation of a new production line for high potency active ingredients (HPAIs). © Cerbios

The additional unit will be Category 3 Safebridge for batches ranging 5-30 kg/batch. The new production line will be partially used for the manufacturing of an HPAI where larger volumes are required thus decreasing the production costs compared to the actual setup. The remaining capacity will be available for Cerbios’ CDMO services and partners, the company said.

Gabriel Haering, CEO of Cerbios, commented: “Considering the conjugation suite for antibody drug conjugates ready this summer and this new production line due in the second half of 2020, our offer to our partners will be six HPAI production units in a single site with space available for future expansions if needed”.

Company

Logo:

Cerbios-Pharma SA

Via Figino 6
6917 Barbengo – Lugano
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.